Stockreport

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study [Yahoo! Finance]

Rallybio Corporation  (RLYB) 
PDF – Data Readouts for Completed Study Expected in 4Q 2025 – NEW HAVEN, Conn., September 25, 2025 BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage [Read more]